Healthcare Medical Devices Biotechnology

Breast Biopsy Market

Global Industry Analysis and Forecast 2024-2031

Pages : 120

Base Year : 2023

Released Year : April 2024

Format :Pdf Ppt Xls

Report ID:KR627

Author : Antriksh P.

Snapshot Icons

Base Year


Snapshot Icons

Forecast Year


Snapshot Icons

Historical Years


Snapshot Icons

Market Value (2023)

USD 2,011.9 Million

Snapshot Icons

Forecasted Value (2031)

USD 3,261.4 Million

Snapshot Icons

CAGR (2024 - 2031)


Snapshot Icons

Fastest Growing Region (2024 - 2031)

Asia Pacific

Snapshot Icons

Largest Region

North America

Snapshot Icons

By Device

Needles, Trays, Localization Wires, Guidance Systems, Others

Snapshot Icons

By Procedure

Needle Breast, Surgical Biopsy, Liquid Biopsy, Stereotactic biopsy, Others

Snapshot Icons

By Application

Hospitals, Clinics, Diagnostic Centres, Others

Breast Biopsy Market Size

The global Breast Biopsy Market was valued at USD 2,011.9 million in 2023 and is projected to reach USD 3,261.4 million by 2031, growing at a CAGR of 6.33% from 2024 to 2031. The rising incidence of breast cancer serves as a significant driver propelling the growth of the breast biopsy market. Breast cancer is one of the most commonly diagnosed cancers globally, affecting millions of individuals each year. Factors such as aging populations, lifestyle changes, hormonal factors, and genetic predisposition contribute to the increasing prevalence of breast cancer. Moreover, advancements in medical screening technologies and increased awareness regarding breast health have led to higher rates of early detection. This, in turn, has resulted in an increase in diagnosed cases, which is fueling the need for accurate diagnostic procedures, such as breast biopsy. As the incidence of breast cancer grows steadily, there is a rising demand for innovative biopsy techniques and technologies that offer precise diagnosis, aiding in better patient management and treatment outcomes.

A breast biopsy is a medical procedure performed to remove a sample of breast tissue for examination under a microscope. It is typically conducted when a suspicious lump or abnormality is detected during a clinical breast examination, mammogram, or other imaging tests. The procedure involves the use of a specialized biopsy needle to extract tissue samples from the breast, under the guidance of imaging techniques such as ultrasound, mammography, or MRI. These samples are then sent to a pathology laboratory for analysis by a pathologist to determine if the tissue is benign (non-cancerous) or malignant (cancerous). Breast biopsies are to be performed using various techniques, including core needle biopsy, vacuum-assisted biopsy, fine needle aspiration, and surgical biopsy. This procedure plays a crucial role in diagnosing breast cancer and other breast abnormalities, guiding treatment decisions, and monitoring disease progression.

Analyst’s Review 

The breast biopsy market is experiencing significant growth, driven by various factors such as the rising incidence of breast cancer, technological advancements in biopsy techniques, and increasing awareness regarding breast health. With the growing prevalence of breast cancer across the globe, there is a growing demand for accurate and minimally invasive diagnostic procedures such as breast biopsy. Additionally, the integration of artificial intelligence and machine learning in biopsy devices is enhancing the efficiency and accuracy of diagnosis, thereby fueling market growth. Key industry players are investing heavily in research and development activities to introduce innovative biopsy technologies and expand their product portfolios. Moreover, companies are undertaking strategic collaborations and partnerships aimed at enhancing distribution networks and expanding market presence. The breast biopsy market is poised to witness substantial growth driven by advancements in technology, increasing healthcare expenditure, and rising awareness regarding breast cancer screening and early detection initiatives worldwide.

Breast Biopsy Market Growth Factors

Growing awareness programs and initiatives for breast cancer screening and early detection are playing a pivotal role in driving the demand for breast biopsy services. Across the globe, numerous organizations, governments, and healthcare institutions are increasingly investing in awareness campaigns, educational programs, and community outreach efforts to promote breast health awareness and the importance of regular screening. These initiatives aim to empower individuals to recognize the signs and symptoms of breast cancer, understand their risk factors, and encourage them to undergo regular screening mammograms or clinical breast examinations. Moreover, advocacy groups and non-profit organizations are playing an active role in raising awareness about breast cancer and organizing events to raise funds for research and support services for patients. As a result of these concerted efforts, there has been a significant increase in the number of women seeking breast cancer screening services, consequently driving the demand for breast biopsy procedures for accurate diagnosis and early intervention, thereby improving patient outcomes.

Limited accessibility to breast biopsy services in underserved regions and remote areas is a significant restraint in the breast biopsy market. Despite advancements in medical technology and healthcare infrastructure, disparities in access to healthcare services persist, particularly in rural and underserved communities. These regions often lack specialized healthcare facilities, trained medical professionals, and diagnostic equipment required to perform breast biopsy procedures. As a result, individuals residing in these areas may face challenges in accessing timely and accurate diagnostic services for breast abnormalities. Limited access to breast biopsy services delays diagnosis and treatment initiation and exacerbates disparities in breast cancer outcomes between urban and rural populations. To address this, governments, healthcare organizations, and stakeholders are focusing on improving healthcare infrastructure, expanding telemedicine services, and implementing outreach programs to ensure equitable access to breast biopsy services for all individuals, regardless of their geographical location.

Breast Biopsy Market Trends

The growing adoption of minimally invasive techniques in breast biopsy procedures is transforming the landscape of breast cancer diagnosis and treatment. Traditionally, surgical biopsy procedures have been the standard approach for obtaining tissue samples from suspicious breast lesions. However, advancements in imaging technology and biopsy devices have led to the development of minimally invasive techniques such as core needle biopsy and vacuum-assisted biopsy. These techniques offer several advantages over surgical biopsy, including reduced patient discomfort, shorter recovery times, and lower healthcare costs. Additionally, minimally invasive biopsies can be performed on an outpatient basis, thereby eliminating the need for hospitalization in most cases. As a result, there has been a significant increase in the adoption of these techniques by healthcare providers and patients. The shift toward minimally invasive biopsy procedures is enhancing patient experience and facilitating earlier diagnosis and intervention, thereby leading to better outcomes in the management of breast cancer and other breast abnormalities.

Segmentation Analysis

The global breast biopsy market is segmented based on device, procedure, application, and geography.

By Device

Based on device, the market is categorized into needles, trays, localization wires, guidance systems, and others. The needles segment accounted for the highest revenue of USD 533.97 million in 2023. Needles are an essential component of various breast biopsy procedures, including core needle biopsy and vacuum-assisted biopsy, enabling the extraction of tissue samples from suspicious breast lesions for pathological analysis. The increasing incidence of breast cancer globally has led to a growing demand for breast biopsy procedures, which is driving the demand for biopsy needles. Moreover, technological advancements in needle design and materials have improved their performance characteristics, such as precision, maneuverability, and tissue yield, thereby enhancing the diagnostic accuracy of breast biopsy procedures. Additionally, the shift toward minimally invasive biopsy techniques has propelled the demand for biopsy needles, as they offer patients a less invasive alternative to traditional surgical biopsies, resulting in reduced procedural discomfort and shorter recovery times. Furthermore, the availability of a wide range of biopsy needle options, including disposable and reusable variants, caters to the diverse needs and preferences of healthcare providers, which is contributing to the expansion of the segment. With people increasingly opting for breast biopsy procedures and the rising demand for accurate diagnostic solutions, the market for biopsy needles is expected to maintain its growth trajectory, which is estimated to drive segmental growth in the forthcoming years.

By Procedure

Based on procedure, the market is classified into needle breast, surgical biopsy, liquid biopsy, stereotactic biopsy, and others. The stereotactic biopsy segment dominated the market with a share of 32.54% in 2023. Stereotactic biopsy is a minimally invasive technique that utilizes specialized imaging technology, such as mammography or MRI, to precisely target and obtain tissue samples from suspicious breast lesions. This technique offers several advantages, including high accuracy in lesion localization, reduced procedure time, and minimal patient discomfort. Moreover, stereotactic biopsy procedures can be performed on an outpatient basis, which makes them convenient for both patients and healthcare providers. The increasing adoption of stereotactic biopsy techniques by radiologists and breast surgeons, coupled with advancements in imaging technology and biopsy devices, has propelled the growth of this segment in the market. Additionally, rising awareness regarding the importance of early detection and diagnosis of breast abnormalities has led to a higher demand for accurate and reliable biopsy procedures namely stereotactic biopsy, thereby contributing to its dominance in the market.

By Application

Based on application, the market is divided into hospitals, clinics, diagnostic centers, and others. The hospitals segment is projected to experience the highest growth at a 6.93% CAGR over the forecast period. Since hospitals serve as primary healthcare centers and are equipped with advanced diagnostic and treatment facilities, including imaging equipment and surgical suites, these facilities have the capabilities required for conducting breast biopsy procedures. Moreover, hospitals often employ multidisciplinary teams of healthcare professionals, including radiologists, oncologists, and breast surgeons. These teams collaborate to provide comprehensive care for patients with breast abnormalities. The increasing prevalence of breast cancer, coupled with rising awareness regarding the importance of early detection and diagnosis, is driving the demand for breast biopsy services in hospital settings. Additionally, hospitals benefit from economies of scale and have the infrastructure to accommodate a higher volume of biopsy procedures. As a result, the hospital segment is anticipated to witness significant growth over the forecast period, catering to the growing demand for breast biopsy services among patients seeking comprehensive and specialized care.

Breast Biopsy Market Regional Analysis

Based on region, the global breast biopsy market is classified into North America, Europe, Asia-Pacific, MEA, and Latin America.

Breast Biopsy Market Size & Share, By Region, 2024-2031

North America secured the highest market share of 41.80% in 2023 due to well-established healthcare infrastructure, advanced diagnostic technologies, and a high level of healthcare expenditure, facilitating widespread access to breast biopsy services. Moreover, increasing initiatives and awareness programs for breast cancer screening and early detection, coupled with favorable reimbursement policies, have contributed to higher adoption rates of breast biopsy procedures in North America. Additionally, the region benefits from the presence of key market players, research institutions, and academic centers focused on breast cancer diagnosis and treatment.

Europe is set to experience considerable expansion at a 6.17% CAGR between 2024 and 2031 owing to increasing awareness regarding breast health, coupled with government-led screening programs and initiatives. Moreover, technological advancements in biopsy techniques and devices, coupled with favorable reimbursement policies, are likely to support regional market growth. Additionally, strategic collaborations between healthcare providers, research institutions, and industry stakeholders aimed at advancing breast cancer diagnosis and treatment are expected to contribute to the growth of the breast biopsy market in Europe. These factors position Europe as a promising market for breast biopsy with significant growth potential in the forecast period, making it an attractive region for investment and expansion.

Competitive Landscape

The global breast biopsy market will provide valuable insight with an emphasis on the fragmented nature of the industry. Prominent players are focusing on several key business strategies such as partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their market shares across different regions. Manufacturers are adopting a range of strategic initiatives, including investments in R&D activities, the establishment of new manufacturing facilities, and supply chain optimization, to strengthen their market standing.

List of Key Companies in Breast Biopsy Market

  • Cardinal Health
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Merit Medical System
  • Trivitron Healthcare
  • Hoffmann-La Roche Ltd.
  • Cook Group
  • Devicor Medical Products, Inc. (Mammotome)

The global Breast Biopsy Market is segmented as:

By Device

  • Needles
  • Trays
  • Localization Wires
  • Guidance Systems
  • Others

By Procedure

  • Needle Breast
  • Surgical Biopsy
  • Liquid Biopsy
  • Stereotactic biopsy
  • Others

By Application

  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • U.K.
    • Spain
    • Germany
    • Italy
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Check Icon Additional Company Profiles
  • Check Icon Additional Countries
  • Check Icon Cross Segment Analysis
  • Check Icon Regional Market Dynamics
  • Check Icon Country-Level Trend Analysis
  • Check Icon Competitive Landscape Customization
  • Check Icon Extended Forecast Years
  • Check Icon Historical Data Up to 5 Years
Frequently Asked Questions (FAQ's)
The global breast biopsy market is projected to reach USD 3,261.4 million by 2031, growing at a CAGR of 6.33% from 2024 to 2031.
The global breast biopsy market was valued at USD 2,011.9 million in 2023.
The breast biopsy market is experiencing significant growth, driven by factors such as the rising incidence of breast cancer, technological advancements in biopsy techniques, and increasing awareness about breast health.
Top manufacturers of breast biopsy market are Cardinal Health, Hologic, Inc., Becton, Dickinson and Company, Merit Medical System, Trivitron Healthcare, PAJUNK, BIOPSYBELL S.R.L., F. Hoffmann-La Roche Ltd., Cook Group, Devicor Medical Products, Inc. (Mammotome), and others.
Asia-Pacific is the fastest growing region with the CAGR of 6.86% in the forecasted period (2024-2031) with the market value forecasted to reach at USD 656.5 million in 2031.
By device, needles will hold the maximum share in the breast biopsy market with the revenue value of USD 923.2 million in 2031.
Get the latest!

Get actionable strategies to empower your business and market domination

  • Deliver Revenue Impact
  • Demand Supply Patterns
  • Market Estimation
  • Real-Time Insights
  • Market Intelligence
  • Lucrative Growth Opportunities
  • Micro & Macro Economic Factors
  • Futuristic Market Solutions
  • Revenue-Driven Results
  • Innovative Thought Leadership